A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
Status:
Withdrawn
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies irinotecan hydrochloride in treating patients with breast
cancer and brain metastases that progressed after whole brain radiation therapy or
stereotactic radiosurgery. Drugs used in chemotherapy, such as irinotecan hydrochloride, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing.